10,014 reports of this reaction
3.6% of all ADALIMUMAB AATY reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for ADALIMUMAB AATY, manufactured by CELLTRION USA, Inc.. There are 10,014 FDA adverse event reports linking ADALIMUMAB AATY to DRUG INEFFECTIVE. This represents approximately 3.6% of all 280,977 adverse event reports for this drug.
Patients taking ADALIMUMAB AATY who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among ADALIMUMAB AATY users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for ADALIMUMAB AATY:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 10,014 FDA reports for ADALIMUMAB AATY. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 3.6% of all adverse event reports for ADALIMUMAB AATY, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking ADALIMUMAB AATY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.